Loading...
•
Sep 25, 2020
Dolby Q4 2020 Earnings Report
Dolby's financial performance declined due to COVID-19 impacts, with revenue and net income decreasing compared to the previous year.
Key Takeaways
Dolby Laboratories reported Q4 2020 financial results with a decrease in revenue to $271.2 million compared to $298.8 million in Q4 2019. GAAP net income decreased to $26.8 million, or $0.26 per diluted share, compared to $43.9 million, or $0.43 per diluted share in Q4 2019. The results reflect the ongoing impact of the COVID-19 pandemic on various markets.
Q4 revenue decreased to $271.2 million from $298.8 million year-over-year.
GAAP net income for Q4 was $26.8 million, or $0.26 per diluted share, down from $43.9 million, or $0.43 per diluted share year-over-year.
Non-GAAP net income for Q4 was $45.8 million, or $0.45 per diluted share, compared to $67.6 million, or $0.66 per diluted share year-over-year.
Cash flows from operations for Q4 was $112.7 million, compared to $130.5 million year-over-year.
Dolby
Dolby
Forward Guidance
Dolby anticipates ongoing impacts from COVID-19 on unit volume shipments and the global cinema market, leading to continued economic uncertainty and difficulty in predicting future results. The company has provided estimates for the first and second quarters of fiscal year 2021, but actual results could differ materially due to the challenging economic environment and the uncertain effects of COVID-19.
Challenges Ahead
- Unit volume shipments continue to be impacted and difficult to predict due to economic uncertainty caused by COVID-19.
- The global cinema market has been adversely impacted by COVID-19 due to site closures or reduced utilization.
- Cinema sites could continue to be negatively affected through the first half of fiscal 2021 or longer.
- Estimates for future periods reflect certain assumptions about the potential impact of COVID-19, which may not materialize.
- Actual results could differ materially from provided estimates due to the challenging economic environment and uncertain effects of COVID-19.